sar425899 sanofi glp-1 glucagon dual agonist Media Centre The effects of Fc fusion
Description
By mid-2025, Lilly had captured approximately 57% of the U.S
The insulinotropic effect of DPP-4 inhibitors explains the phenomenon that this class increasingly is replacing the use of sulfonylureas as insulin releasing agents
J Neurogastroenterol Motil 2011
Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al
There were also more frequent arrhythmias requiring anti-arrhythmic agents in the control group [50]
These may not be FDA-approved, and they can create safety uncertainty
